Carol A Huff

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Bone marrow transplantation for multiple myeloma: where we are today
    Carol Ann Huff
    Johns Hopkins University, Department of Oncology, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 14:147-51. 2002
  2. ncbi request reprint Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
  3. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
  4. pmc The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
  5. ncbi request reprint Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
  7. pmc Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
  8. ncbi request reprint Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, MD, USA
    Br J Haematol 130:373-81. 2005
  9. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
  10. pmc Multiple myeloma cancer stem cells
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, CRB245, 1650 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:2895-900. 2008

Research Grants

  1. Translational Research in Multiple Myeloma
    CAROL HUFF; Fiscal Year: 2006

Detail Information

Publications20

  1. ncbi request reprint Bone marrow transplantation for multiple myeloma: where we are today
    Carol Ann Huff
    Johns Hopkins University, Department of Oncology, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 14:147-51. 2002
    ....
  2. ncbi request reprint Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
    ..Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers...
  3. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  4. pmc The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
    ..In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches...
  5. ncbi request reprint Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
    ..Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD...
  6. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  7. pmc Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
    ..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients...
  8. ncbi request reprint Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, MD, USA
    Br J Haematol 130:373-81. 2005
    ..At least part of the clinical effect of IFN in CML appears to result from its ability to differentiate primitive CML progenitors...
  9. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  10. pmc Multiple myeloma cancer stem cells
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, CRB245, 1650 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:2895-900. 2008
    ..We review evidence that functional heterogeneity exists in multiple myeloma and discuss potential strategies and clinical implications of the stem-cell model of cancer in this disease...
  11. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  12. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier BolaƱos-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  13. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  14. ncbi request reprint Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
    ..These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM...
  15. pmc Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    ..These data suggest that MM "stem cells" are CD138- B cells with the ability to replicate and subsequently differentiate into malignant CD138+ plasma cells...
  16. ncbi request reprint Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
    ..The combined use of pharmacologic differentiating agents and growth factors may improve the clinical efficacy of differentiation therapy in APL...
  17. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  18. pmc Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses
    Kimberly Noonan
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 18:1426-34. 2012
    ..To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses...
  19. ncbi request reprint A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma
    Usha Sunkara
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    J Interferon Cytokine Res 24:37-41. 2004
    ..The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease > or =6 months remain of interest...
  20. ncbi request reprint Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007

Research Grants1

  1. Translational Research in Multiple Myeloma
    CAROL HUFF; Fiscal Year: 2006
    ..abstract_text> ..